A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Exclusion Criteria

• •1. Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
• •2. Prior receipt of any immune-mediated therapy
• •3. Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed
• •4. Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent
• •5. Subjects with a history of Grade 3 or greater thromboembolic events in the prior 12 months or thromboembolic event of any grade with ongoing symptoms
• •6. Subjects with prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment
• •7. Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment
• •8. HIV, Hep A, B, or C
• •9. History of primary immunodeficiency, solid organ transplantation, or active tuberculosis
• •10. Other invasive malignancy within 2 years
• •11. Known allergy or hypersensitivity to investigational product formulations
• •12. History of more than one event of infusion related reactions (IRR) requiring permanent discontinuation of IV drug treatment
• •13. Active grade 3 or greater edema
• •14. Uncontrolled intercurrent illness
• •15. Any history of leptomeningeal disease or cord compression
• •16. Untreated CNS metastatic disease.
• •17. Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment.
• •18. Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment
• •19. Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery
• •20. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
• •21. Subjects who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures
• •22. Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results